Researchers reveal that early life factors, especially within the first 2,000 days, play a critical role in shaping future obesity risk. Addressing these factors with integrated interventions could combat the global childhood obesity crisis.
Inventiva secures up to $380m for MASH treatment lanifibranor – Pharmaceutical Technology
The FDA approved the first treatment for MASH in March this year. Image credit: Shutterstock/ Iurii Motov. Inventiva has secured up to €348m ($380m) in
October 14, 2024